MGMariano García-Magariño

Mariano García-Magariño

*This is an algorithmically generated author record based on publicly available information.

Mariano García-Magariño has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Neurotrophic Factors and Their Receptors Are Altered by the Mere Partial IGF-1 Deficiency

    by Inma Castilla-Cortázar, Ignacio Iturrieta, Mariano García-Magariño, Juan E. Puche, Irene Martín-Estal, Gabriel A. Aguirre, Giovana Femat-Roldan, Leonel Cantu-Martinez, Úrsula Muñoz


  • Open Access

    Primary growth hormone insensitivity and psychomotor delay

    by Inma Castilla‐Cortazar, Julieta Rodríguez De Ita, Gabriel A. Aguirre, Joel Rodríguez‐Rivera, Mariano García‐Magariño, Irene Martín‐Estal, Óscar Flores‐Caloca, Carlos Diaz‐Olachea

    Key Clinical Message: We report a case of short stature irresponsive to growth hormone (GH) replacement therapy. LowGHresponse to provocative tests and undetectableIGF‐1 levels had suggestedGHdeficiency, while response to therapy indicatedGHinsensitivity. Molecular evaluation of theGH/IGF‐1 axis should be performed in these cases to improve diagnosis and therapy.


  • Open Access

    Mexican case report of a never‐treated Laron syndrome patient evolving to metabolic syndrome, type 2 diabetes, and stroke

    by Inma Castilla‐Cortazar, Giovana Femat‐Roldán, Joel Rodríguez‐Rivera, Gabriel A. Aguirre, Mariano García‐Magariño, Irene Martín‐Estal, Luis Espinosa, Carlos Díaz‐Olachea

    Key Clinical Message: Glucose and lipid profile together with blood pressure should always be considered for low sera‐IGF‐1 patients. Even when adulthood is reached, IGF‐1 therapy in these patients should be pursued as metabolic and protective cellular effects could be triggered. Real incidence of growth hormone insensitivity is still to be uncovered.


  • Open Access

    Experimental approach to IGF-1 therapy in CCl4-induced acute liver damage in healthy controls and mice with partial IGF-1 deficiency

    by Luis A. Morales-Garza, Juan E. Puche, Gabriel A. Aguirre, Úrsula Muñoz, Mariano García-Magariño, Rocío G. De la Garza, Inma Castilla-Cortazar

    Cell necrosis, oxidative damage, and fibrogenesis are involved in cirrhosis development, a condition in which insulin-like growth factor 1 (IGF-1) levels are diminished. This study evaluates whether the exogenous administration of low doses of IGF-1 can induce hepatoprotection in acute carbon tetrachloride (CCl4)-induced liver damage compared to healthy controls (Wt Igf +/+). Additionally, the impact of IGF-1 deficiency on a damaged liver was investigated in mice with a partial deficit of this hormone (Hz Igf1 +/−). Three groups of 25 ± 5-week-old healthy male mice (Wt Igf +/+) were included in the protocol: untreated controls (Wt). Controls that received CCl4 (Wt + CCl4) and Wt + CCl4 were treated subcutaneously with IGF-1 (2 µg/100 g body weight/day) for 10 days (Wt + CCl4 + IGF1). In parallel, three IGF-1-deficient mice (Hz Igf1 +/−) groups were studied: untreated Hz, Hz + CCl4, and Hz + CCl4 + IGF-1. Microarray and real-time quantitative polymerase chain reaction (RT-qPCR) analyses, serum aminotransferases levels, liver histology, and malondialdehyde (MDA) levels were assessed at the end of the treatment in all groups. All data represent mean ± SEM. An altered gene coding expression pattern for proteins of the extracellular matrix, fibrosis, and cellular protection were found, as compared to healthy controls, in which IGF-1 therapy normalized in the series including healthy mice. Liver histology showed that Wt + CCl4 + IGF1 mice had less oxidative damage, fibrosis, lymphocytic infiltrate, and cellular changes when compared to the Wt + CCl4. Moreover, there was a correlation between MDA levels and the histological damage score (Pearson’s r = 0.858). In the IGF-1-deficient mice series, similar findings were identified, denoting a much more vulnerable hepatic parenchyma. IGF1 treatment improved the biochemistry, histology, and genetic expression of pro-regenerative and cytoprotective factors in both series (healthy and IGF-1-deficient mice) with acute liver damage, suggesting that low doses of IGF-1, in acute liver damage, could be a feasible therapeutic option.


  • Open Access

    Fanconi Anemia and Laron Syndrome

    by Inma Castilla-Cortazar, Julieta Rodriguez de Ita, Gabriel Amador Aguirre, Fabiola Castorena-Torres, Jesús Ortiz-Urbina, Mariano García-Magariño, Rocío García de la Garza, Carlos Diaz Olachea, Martha Irma Elizondo Leal


  • Open Access

    IGF-1 modulates gene expression of proteins involved in inflammation, cytoskeleton, and liver architecture

    by Vj Lara-Diaz, I Castilla-Cortazar, I Martín-Estal, M García-Magariño, Ga Aguirre, Je Puche, Rg de la Garza, LA Morales, U Muñoz

    Even though the liver synthesizes most of circulating IGF-1, it lacks its receptor under physiological conditions. However, according to previous studies, a damaged liver expresses the receptor. For this reason, herein, we examine hepatic histology and expression of genes encoding proteins of the cytoskeleton, extracellular matrix, and cell-cell molecules and inflammation-related proteins. A partial IGF-1 deficiency murine model was used to investigate IGF-1’s effects on liver by comparing wild-type controls, heterozygous igf1+/−, and heterozygous mice treated with IGF-1 for 10 days. Histology, microarray for mRNA gene expression, RT-qPCR, and lipid peroxidation were assessed. Microarray analyses revealed significant underexpression of igf1 in heterozygous mice compared to control mice, restoring normal liver expression after treatment, which then normalized its circulating levels. IGF-1 receptor mRNA was overexpressed in Hz mice liver, while treated mice displayed a similar expression to that of the controls. Heterozygous mice showed overexpression of several genes encoding proteins related to inflammatory and acute-phase proteins and underexpression or overexpression of genes which coded for extracellular matrix, cytoskeleton, and cell junction components. Histology revealed an altered hepatic architecture. In addition, liver oxidative damage was found increased in the heterozygous group. The mere IGF-1 partial deficiency is associated with relevant alterations of the hepatic architecture and expression of genes involved in cytoskeleton, hepatocyte polarity, cell junctions, and extracellular matrix proteins. Moreover, it induces hepatic expression of the IGF-1 receptor and elevated acute-phase and inflammation mediators, which all resulted in liver oxidative damage.


  • Partial IGF‐1 deficiency induces brain oxidative damage and edema, which are ameliorated by replacement therapy

    by Juan E. Puche, Úrsula Muñoz, Mariano García‐Magariño, María C. Sádaba, Inma Castilla‐Cortázar

    Insulin‐like growth factor 1 (IGF‐1) induces multiple cytoprotective effects on every tissue, including the brain. Since the mechanisms by which IGF‐1 produces neuroprotection are not fully understood, the aim of this work was to delve into the underlying mechanisms. IGF‐1 deficient mice (Hz) were compared with wild type (WT) and Hz mice treated with low doses of IGF‐1 (2 µg/100 g body weight/day) for 10 days (Hz + IGF). Gene expression, quantitative PCR, histology, and magnetic resonance imaging were performed in the three groups. IGF‐1 deficiency induced increased oxidative damage determined by markers of lipid peroxidation and hypoxia, as well as gene expression of heat shock proteins, antioxidant enzymes, and molecules involved in inflammation, apoptosis, and mitochondrial protection. These changes correlated with edema and learning impairment in Hz mice. IGF‐1 therapy improved all these alterations. In conclusion, IGF‐1 deficiency is responsible for increased brain oxidative damage, edema, and impaired learning and memory capabilities which are rescued by IGF‐1 replacement therapy. © 2016 BioFactors, 42(1):60–79, 2016


  • Mechanisms Underlying Testicular Damage and Dysfunction in Mice With Partial IGF-1 Deficiency and the Effectiveness of IGF-1 Replacement Therapy

    by Inma Castilla-Cortázar, Alberto Gago, Úrsula Muñoz, Elena Ávila-Gallego, Lucía Guerra-Menéndez, María Cruz Sádaba, Mariano García-Magariño, María Olleros Santos-Ruiz, G.A. Aguirre, Juan Enrique Puche


  • Open Access

    Altered liver expression of genes involved in lipid and glucose metabolism in mice with partial IGF-1 deficiency: an experimental approach to metabolic syndrome

    by J. Rodríguez De Ita, I. Castilla-Cortázar, G. A. Aguirre, C. Sánchez-Yago, M. Olleros Santos-Ruiz, L. Guerra-Menéndez, I. Martín-Estal, M. García-Magariño, V. J. Lara-Díaz, J. E. Puche, et al.

    Insulin growth factor 1 (IGF-1) has multiple effects on metabolism. Much evidence suggests that the deficiency of this hormone increases insulin resistance, impairs lipid metabolism, augments oxidative damage and deregulates the neuro-hormonal axis. An inverse relationship between IGF-1 levels and the prevalence of Metabolic Syndrome (MetS) with its cardiovascular complications has been identified. However, the underlying mechanisms linking IGF-1 and MetS are still poorly understood. In order to elucidate such mechanisms, the aim of this work was to study, in mice with partial IGF-1 deficiency, liver expression of genes involved in glucose and lipid metabolism as well as serum levels of glucose, triglycerides and cholesterol, as well as liver malondialdehyde (MDA) levels, as a marker for oxidative damage. Three experimental groups were studied in parallel: Controls (CO), wild type mice (igf-1 +/+); untreated heterozygous mice (Hz, igf-1 +/−) and Hz (igf-1 +/−) mice treated with low doses of IGF-1 for 10 days (Hz + IGF-1). A reduction of IGF-1 serum levels in the Hz group was found, which was normalized by IGF-1 therapy. Serum levels of glucose, triglycerides and cholesterol were significantly increased in the untreated Hz group as compared to both controls and Hz + IGF-1 groups. The expression of genes involved in gluconeogenesis, glycogenolysis, lipid synthesis and transport, and catabolism were altered in untreated Hz animals and the expression of most of them was normalized by IGF-1 therapy; MDA was also significantly increased in the Hz untreated group. The mere partial IGF-1 deficiency is responsible for the reduction in the expression of genes involved in glucose and lipid metabolism, resulting in dyslipidemia and hyperglycemia. Such genetic alterations may seriously contribute to the establishment of MetS.